Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018
Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018
Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
SAN FRANCISCO, May 09, 2018 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the first quarter of 2018 and provided an update on the company’s recent developments.
“FibroGen and AstraZeneca are preparing to complete patient enrollment in five Phase 3 roxadustat CKD anemia trials this quarter. We look forward to reporting topline data in the fourth quarter of this year. With our partners, we are …
Source: Original Article